Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01244633 · ClinicalTrials.gov registry record · Phase 1
Ecopipam Treatment of Tourette Syndrome
A Phase 1 study of Tourette's Syndrome, sponsored by Psyadon Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 4
- Study locations
NCT01244633: Completed Phase 1 study of Tourette's Syndrome, sponsored by Psyadon Pharma.
NCT01244633 is a Phase 1 study of Tourette's Syndrome that has completed, run by Psyadon Pharma. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01244633, a Phase 1 study of Tourette's Syndrome, has completed, sponsored by Psyadon Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 4
- Study locations
Study Summary
Tourette's Syndrome is a neurological disease characterized by verbal and motor tics. The currently available drug treatments are considered to be inadequate. This clinical trial is designed to test if ecopipam is effective for the treatment of Tourette's Syndrome in adults.
Primary Outcome
The Yale Global Tic Severity Score is a composite of subject reported severity of motor (range 0-25) and vocal (range 0-25) tics , as well as an impairment score (range 0-50). The outcome we are using is the Total Tic Severity score which is the sum of the motor and vocal tic severity scores (range 0-50). The higher the score on this scale, the more severe the symptoms. A positive drug effect is associated with a decrease from baseline.
Conditions Studied
Interventions
- DRUG Ecopipam
Study Locations (4)
Maryland
- Johns Hopkins University - Baltimore
New Jersey
- Atlantic Neuroscience Institute Overlook Hospital - Summit
New York
- North Shore Hospital - Manhasset
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
What the finished NCT01244633 record still lists
NCT01244633 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Tourette's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Ecopipam is the first listed.
NCT01244633 reports a single indexed study location in Maryland, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT01244633 about?
NCT01244633 is a clinical study titled "Ecopipam Treatment of Tourette Syndrome". Tourette's Syndrome is a neurological disease characterized by verbal and motor tics. The currently available drug treatments are considered to be inadequate. This clinical trial is designed to test if ecopipam is effective for the treatment of Tourette's Syndrome in adults.
What is the current status of trial NCT01244633?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-10. Estimated completion is 2013-07.
What conditions does trial NCT01244633 study?
This clinical trial studies the following conditions: Tourette's Syndrome.
What interventions are being tested in trial NCT01244633?
The interventions under investigation include: Ecopipam (DRUG).
Who is sponsoring clinical trial NCT01244633?
This trial is sponsored by Psyadon Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01244633 being conducted?
This trial has 4 study locations across Maryland, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tourette's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01244633's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia